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ABSTRACT 
The conventional old treatment method for cancer therapy is associated 
with severe side effects along with several limitations. Therefore, 
searching and developing new methods for cancer became crucial. This 
mini review was devoted on the design and synthesis of prodrugs for 
cancer treatment. The methods discussed include targeted prodrugs 
which are depending on the presence of unique cellular conditions at 
the desired target, especially the availability of certain enzymes and 
transporters at these target sites, antibody directed enzyme prodrug 
therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT) 
which is considered one of the important strategies for the treatment of 
cancer and prodrugs based on enzyme models that have been 
advocated to understand enzyme catalysis. In this approach, a design of  
prodrugs is accomplished using computational calculations based on molecular orbital and 
molecular mechanics methods. Correlations between experimental and calculated rate values 
for some intramolecular processes provided a tool to predict thermodynamic and kinetic 
parameters for intramolecular processes that can be utilized as prodrugs linkers. This 
approach does not require any enzyme to catalyze the prodrug interconversion. The 
interconversion rate is solely dependent on the factors govern the limiting step of the 
intramolecular process. 
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Cancer is defined as uncontrolled growth of abnormal cells. The cancerous cells may invade 
the nearby tissues (cells) and spread to other parts of the body through the blood and lymph-
systems. The anticancer agents used in chemotherapy are systemic anti-proliferative agents 
that kill the dividing cells. These cytotoxic agents include antimetabolites, alkylating agents; 
DNA-complexing agents, mitosis inhibitors and hormones, and they interfere with some 
aspect of DNA replication, cell division and cell translation or repair. These agents mainly 
rely on enhanced proliferative rate of cancer cells, which means that they are not truly 
selective for cancer cells. The prolonged use of chemotherapy results in lethal damage to 
proliferating non-cancerous cells and this is mainly true in the treatment of solid tumors. 
Studies have shown that cytotoxins use in patients having appreciable tumor burdens leads to 
remissions of varying degrees which is followed by re-growth and spread of more malignant 
forms of the cancer. Although extensive studies and trials have been carried out in the last 
several decades, the long-term outlook for patients with malignant cancer forms is still 
discouraging. Therefore, it is a must to invoke innovative approaches for the design of new 
anticancer drugs with reduced toxicity and better therapeutic indices.
[1]
 
 
Prodrug therapy provides less reactive and cytotoxic form of anticancer drugs. The lack of 
selectivity of anticancer drugs results in significant toxicity to noncancerous proliferating 
cells. These toxicities along with drug resistance exhibited by the solid tumors are considered 
as a major challenge that results in poor prognosis for patients.
[2]
 
 
The term "prodrug" or ―predrug‖ was first used by Albert to define or describe 
therapeutically inactive molecule that can be utilized to modify the physicochemical 
properties of an active therapeutic drug for enhancing its effectiveness and eliminate or 
suppress its toxicity and/or its adverse effects. Prodrugs are chemically made by attaching a 
parent active drug to non-toxic promoiety and upon their exposure to physiological 
environment (in vivo) they undergo enzymatic or chemical cleavage to furnish the active 
form and a non-toxic linker (promoiety).
[3-   32]
  
 
The aim of using prodrugs is to achieve optimized ADME (absorption, distribution, 
metabolism, and excretion) properties and to increase selectivity of drugs to their target sites.  
The prodrug approach has been utilized to overcome several drug‘s barriers and optimize 
drug‘s clinical application. Nowadays, prodrug design has succeeded to offer efficient and 
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selective drug delivery systems. For instance, targeted prodrug approach, with the aid of gene 
delivery and controlled expression of enzymes and carrier proteins has played a major role in 
providing a precise and efficient drug delivery which contributed much to the enhancement 
of the drug‘s therapeutic effect.[9-15] 
  
The ways by which the prodrug approach can be utilized include: (1) an Improvement of the 
active drug‘s solubility and consequently its bioavailability. Statistics have shown that more 
than 30% of drug discovery compounds have low aqueous solubility,
[33]
 (2) increasing the 
active drug‘s permeability and absorption,[21] (3) modifying the drug‘s distribution profile,[34-
35]
 (4) prevention the active drug‘s fast metabolism and excretion,[36-39] (5) reducing the active 
drug‘s toxicity by altering one or more of the ADME barriers but more often is achieved by 
targeting drugs to desired cells and tissues via site-selective drug delivery.
[40-42]
 and (6) 
prolong the active drug activity such as in the case of 6-mercaptopurine which is used to 
suppress the immune system (organ transplants), however, its elimination time is too fast. A 
prodrug that slowly is converted to the active drug allows a sustained release of the drug‘s 
active form.
[9-15]
 
  
For synthesizing a prodrug from its parent active drug, the latter must contain a functional 
group that can be utilized to form a chemical linkage with a linker (promoiety) and this 
linkage should be labile and easy to cleave by enzyme catalyzed or un-catalyzed chemical 
cleavage or under a change in the physiological medium‘s pH.[43]  
 
The commonly used linkages in prodrug design are carboxylic ester, phosphate ester, 
carbonate, carbamate, amide, oxime, imine or disulfide (Figure 1). 
 
Figure 1: Commonly used linkages in prodrugs design. 
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Ester is the most common linkage used in prodrug design since it is easy to be synthesizes 
and its function groups, hydroxyl and carboxyl acid, are widely available in most parent 
active drugs.
[44]
 
 
Amide bond is another commonly used linkage in prodrug design. It is derived from amine 
and a carboxyl group. The amide bond has higher enzymatic stability than ester bond. Several 
other types of linkers including oximes, imines, disulfide and uncleavable thioether bond 
have also been used in prodrug design.
[45-50]
 
 
Anti-cancer prodrugs and conjugates design involves the synthesis of inactive moiety that is 
converted to its active form inside the body at the site of action. Targeting strategies of anti-
cancer agents have attempted to take advantage of low extracellular pH, high enzymes levels 
in tumor tissues, the hypoxic environment inside the tumor, and tumor-specific antigens 
expressed on tumor cell surfaces.
[41]
 
 
The drug release in most of the prodrugs is achieved by conjugating the drug to the carrier 
through a linker that incorporates a pre-determined breaking point, in which the drug can be 
activated on the target‘s active site. The general design of carrier-linked anti-cancer prodrug 
is shown in Figure 2. 
 
 
Figure 2: General design of carrier-linked anticancer prodrugs. 
 
TARGETING STRATEGIES  
The prodrugs can be targeted selectively to tumors either by active or passive targeting 
strategies. 
 
ACTIVE TARGETTING  
Tumor specific antigens or receptors—conjugate drug molecules to monoclonal antibodies 
(mAbs) or ligands. 
In the period between 1998 and 2004, five chimeric or humanized antibodies including 
rituximab (Rituxan), trastuzumab (Herceptin), alemtuzumab (campath), bevacizumab 
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(Avastin) and cetuximab (Erbitux) was approved by the FDA for the treatment of 
hematological and solid tumors. A large number of anti-cancer drugs have been studied to be 
utilized in drug antibody conjugates. Among those agents are doxorubicin, CC-1065 (from 
Streptomyces zelensis), second-generation taxanes, monomethyl auristatin E, and 
geldanamycin. An important and prominent example used utilizing this approach is the 
cantuzumab mertansine conjugate of DM1 (Figure 3).
[51-80]
  
 
 
Figure 3: Cantuzumb mertansine (huC242-DM1) 
 
Mylotarg (gemtuzumab, Wyeth) is the only immunoconjugate that was approved by the FDA 
for the treatment of cancer. This immunoconjugate consists of humanized anti-CD33 mAb 
linked to the cytotoxic antibiotic ozogamicin.
[77]
 In addition, there are about twenty antibody-
drug conjugates under clinical trials. 
 
Mylotarg is antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). 
This prodrug was approved in 2000 by the FDA, and a post-marketing study was begun in 
2004. Unfortunately, this conjugate (Mylotarg) was withdrawn from the market in 2010 
because of its ineffectiveness and severe side effects that were observed in post-approval 
clinical trial. 
 
On the other hand, active targeting can be achieved by binding drugs to ligands that display 
high affinity for a particular receptor, (folic) the folate receptor (FR) which is over-expressed 
in many tumors, including those of the breast, lung, kidney and brain. FR binds folic acid 
(folate) with high affinity. Examples of such approach include folate conjugates of cytotoxic 
drugs such as camptothecin, taxol, mitomycin C, and folate-tethered protein toxins such as 
momordin and the Pseudomonas exotoxin.
[51-80]
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Antibody-directed enzyme prodrug therapy (ADEPT) 
Antibody-directed enzyme prodrug therapy (ADEPT) is another approach for delivering 
anticancer drugs selectively to tumor cells. In this approach, there is a conjugation between 
an enzyme and tumor-specific antibody. Selective localization of the enzyme is achieved by 
the antibody and thus, reduced side effects are observed. An example of such approach is A 
CC-1065 analogue which was conjugated with a cephalosporin to provide a prodrug system. 
The resulting prodrug is expected to have reduced toxic effects when compared to its 
corresponding parent active drug. The prodrug system was designed such that it will undergo 
cleavage catalyzed by β–lactamases, localized on the tumor cell surface with the help of the 
conjugated antibody, to its active form (Figure 4). The selective activation of the mentioned 
prodrug at the core of the tumor site has the potential to lead to enhanced antitumor 
therapeutic efficacy.
[70, 81]
 
 
 
Figure 4: A prodrug consists of CC-1065 analogue conjugated to a cephalosporin and 
activated by β–lactamase. 
 
ZD2767P (prodrug) is another example of prodrug was developed  to investigate tumor 
targeting of the antibody-enzyme conjugate, and to study a new prodrug (bisiodophenol 
mustard, ZD2767P) whose activated form has a short half-life and is highly potent. ZD2767P 
was developed to reduce the problem associated with long-acting active drug (Figure 5).
[82-84]
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Figure 5: Representative example of prodrugs using the ADEPT system. 
 
Gene-directed enzyme prodrug therapy (GDEPT)
[85-101]
 
GDEPT known as suicide gene therapy involves a gene for a foreign enzyme delivery to the 
core of tumor cells without reaching the surrounding healthy cells. HSV TK with the 
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nucleoside analogue GCV is considered as the most well-investigated enzyme/prodrug 
strategy in cancer GDEPT therapy.  
 
GCV and its related derivatives, mainly used in the treatment of HSV infection in humans, 
characterized by poor substrates for the mammalian nucleoside monophosphate kinase 
enzyme, but can be converted (1000-fold or more) efficiently to the monophosphate by TK 
from HSV 1 leading to a number of toxic metabolites; the most active metabolite is the 
triphosphates (Figure 6). The competition of GCV-triphosphate with deoxyguanosine 
triphosphate for incorporation into elongating DNA during cell division, results in inhibition 
of the DNA polymerase and consequently to a breakdown of single strand. These unique 
properties make the HSV TK/GCV combination perfectly suitable for the eradication of 
rapidly dividing tumor cells invading non-proliferating tissue.  
 
 
Figure 6. Metabolism of the prodrug ganciclovir (GCV). 
 
 GCV is specially phosphorylated by the herpes simplex virus 1 thymidine kinase (HSV TK) 
to its monophosphate. Subsequently, GCV-monophosphate is converted to the di- and 
triphosphate forms by guanylate kinase and other cellular enzymes and can be incorporated 
into elongating DNA, causing inhibition of the DNA replication and single strand breaks. 
 
Several gene or treatment modalities were investigated to improve the GDEPT efficiency 
because it was realized that the treatment with a single GDEPT strategy might lead to partial 
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response and thus a combination of CD-HSV TK fusion genes was delivered followed by the 
prodrug GCV and 5-FC and as a result higher efficacy for the combined system was 
achieved. This system provided good results when was used in combination with 
radiotherapy.
[85-101]
  
 
CYTOSINE DEAMINASE (CD)/5-FLUOROCYTOSINE (5-FC) 
This system consisting of CD and 5-FC and relays on the production of a toxic nucleotide 
analogue. The enzyme CD, found in certain bacteria and fungi catalyzes the hydrolytic 
deamination of cytosine to uracil. Thus it can convert the non-toxic prodrug 5-FC to 5-
fuorouracil (5-FU), which is then transformed by cellular enzymes to potent pyrimidine 
antimetabolites, 5-FdUMP, 5-FdUTP and 5-FUTP (Figure 7). 5-FU is the drug of choice in 
the treatment of colorectal cancer and it is widely used in cancer chemotherapy.
[102]
  
 
Figure 7: Conversion of 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) by E. coli 
cytosine deaminase (CD). 5-FU is converted by cellular enzymes into 5-
fluorodeoxyuridine-50-monophosphate (5-FdUMP), 5-uorodeoxyuridine-50-
triphosphate (5-FdUTP) and 5-fluorouridine-50-triphosphate (5-FUTP).  
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Membrane transporters
[103]
 
Membrane transporters are integral membrane proteins that control the movement of amino 
acids, sugar, nucleosides, and peptides across cell membrane. It is known that, membrane 
transporters have been used to improve the bioavailability of polar drugs by the prodrug 
strategy. 
 
Membrane transporters include glucose transporter, peptide and amino-acid transporter. 
Peptide transporter is the most attractive and widely used transporter for the prodrug design.  
Peptide transporters are divided into two categories: (i) peptide transporters PEPT1 and 
PEPT2; and (ii) peptide/ histidine transporters PHT1 and PHT2.   
 
PEPT1 transporter is characterized by over-expression in many cancer cells including the 
malignant ductal pancreatic cancer cell lines AsPc-1 and Capan-2, and human fibrosarcomas 
cell line HT-1080, and this over expression is not seen in normal cell. The anticancer drug 
floxuridine used for metastatic colon cancer and hepatic metastases was linked to PEPT1 via 
an ester linkage to provide a prodrug based on the above mentioned approach.  Studies have 
shown that this prodrug exhibited a higher uptake in PEPT1 over-expressing tumor cells. As 
a result, a selective growth inhibition was observed in tumor cells over-expressing PEPT1, 
but not in PEPT1-negative tumor cells. 
 
Another example utilizing this approach was applied for Gemcitabine, a nucleoside analog 
compound that is used clinically as an efficient anti-neoplastic agent. Amino acid ester 
conjugates of Gemcitabine were shown to serve as substrate for either one or both of the 
peptide transporters PEPT1 and PEPT2. 
 
Another important membrane transporter for targeted prodrug is the sodium-dependent 
multivitamin transporter (SMVT).  
 
PASSIVE TARGETTING
[103] 
Prodrugs can also be targeted to tumors by passive targeting. This is achieved by attaching 
the drug to large molecules or nanoparticles that act as inert carriers. This strategy depends on 
enhanced permeability and retention (EPR) effect of tumor environment. 
 
Drug Release at the Tumor Site
[103]
 
When Prodrug is being inside the tumor, it must be activated to exert its antitumor activity. 
The activation of the free drug can occur intracellularly or extracellular.  
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Enzymatic cleavage
[103]
 
Prodrug activation can be achieved by tumor-associated enzymes, which are expressed either 
intracellularly or extracellular by cancerous cells. The drug release by enzymatic cleavage is 
achieved by the following mechanisms: (a) the active drug is directly linked to a peptide 
linker and the linkage between the two moieties is cleaved by the enzyme to provide the 
active drug and (b) an enzymatic cleavage to the peptide sequence is taking place to release 
the drug-peptide derivative, which is in a following step cleaved to the active drug. Another 
possibility is to attach self-immolative spacer to the peptide promoiety.
[103]
 
 
Acid sensitive linkers
[103]
 
Acid sensitive linkages are used in the prodrug approach and they are intended to cleave 
under the acidic conditions present in tumors, lysosomes, and endosomes. The environment 
in tumor tissues is more acidic (0.5–1.0 pH units lower) than the normal tissues. These 
changes in pH can be used to cleave acid sensitive prodrugs extracellular, especially when the 
prodrug stays in tumor interstitium for long durations.  
 
Examples of acid sensitive linkage used in prodrug and conjugate design are imine, 
hydrazone, carboxylic hydrazine, ketal, acetal, cis-aconityl and trityl bonds (Figure 8). 
 
 
Figure 8: Acid sensitive linkages used in prodrug design. 
 
Hypoxia
[103-106]
 
A common mechanism for converting non-toxic prodrug to a toxic drug in a hypoxic 
environment include reduction by one or two electrons of the prodrug to form a radical that 
becomes a substrate for back-oxidation by an oxygen to the original compound. 
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Examples of hypoxic prodrugs in clinical trials include: anthraquinone derivative (AQ4N). 
Three prodrug systems have been reported to be efficiently activated by ionizing radiations 
under hypoxia: nitrobenzyl quaternary ammonium salts, cobalt (III) complexes, and 
oxypropyl-substituted 5-fluoruracil derivatives.  
 
Immunotoxins
[103-107] 
Antibody conjugates of highly potent drugs (DOX is frequently used) are called 
Immunotoxins. Immunotoxins contain a toxin made by insects, plants or microorganisms, 
Examples for Immunotoxins include Pseudomonas exotoxin A (PE), diphtheria toxin (DT), 
and ricin. Several Immunotoxins were constructed by conjugating mAbs to whole toxins via a 
disulfide linkage. The disulfide bonds are cleaved in the reducing environment present in 
endosomes/ lysosomes and the process usually involves thiol-exchange reaction. A widely 
investigated example is the BR96-DOX conjugate. Promising immune-toxins currently in 
clinical trials include TransMID 107 (transferrin-CRM107) and PRECISE (IL13-PEI-301-
R03). 
 
Self-immolative spacers
[108]
 
The self-immolative spacers have three components: drug, linker, and trigger. A reaction 
takes place between trigger and the linker to form a drug-linker derivative, which then 
degrades spontaneously by cyclization or elimination to release the free drug (Figure 9). 
 
Figure 9: Self-immolative mustard prodrug. 
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ANTI-CANCER PRODRUGS BASED ON INTRAMOLECULAR PROCESSES
[109-153]
 
Three myelodysplastic syndromes (MDS) agents were approved by the U.S. Food and Drug 
Administration: 5-azacitidine, decitabine and cytarabine (Figure 10). Chemotherapy with the 
hypomethylating agents, 5-azacytidine and decitabine resulted in a decrease of blood 
transfusion requirements and progression retard of MDS to acute myelogenous leukemia 
(AML). All three nucleoside agents have short half-life values (t1/2). Design and synthesis of 
a slow degrading prodrug can provide sustained exposure to the drug during the treatment of 
MDS patients. This might result in better clinical outcome, more convenient dosing regimens 
and potentially less adverse effects. 
 
Another example, decitabine has to be administered by continuous IV infusion, if a prodrug is 
designed to be breakdown in a slow release manner by SC route, optimum MDS maintenance 
treatment could be imminent.  
 
 
Figure 10: Chemical structures of the aza-nucleosides, cytarabine, azacitidine and 
decitabine. 
 
By improving azacitidine, cytarabine and decitabine pharmacokinetic properties the drug 
absorption via a variety of administration routes, especially the SC injection route, can be 
facilitated. Utilizing a carrier-linked prodrug strategy by linking the aza nucleoside drugs to a 
carrier moiety can provide a chemical device capable of penetrating the membrane tissues 
and releasing the aza nucleoside in a controlled manner. 
 
In the past five years, karaman‘s group has unraveled a respected number of intramolecular 
processes which were utilized as enzyme models. Based on DFT calculations on a proton 
transfer reaction in some of Kirby‘s enzyme models, Karaman‘s group have designed three 
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prodrugs of aza nucleoside. As shown in Figure 11, the aza nucleoside prodrugs ProD 1- 
ProD 3 have N, N-dimethylanilinium group (hydrophilic moiety) and a lipophilic moiety (the 
rest of the prodrug), where the combination of both moieties secures a moderate HLB. 
Furthermore, in a physiologic environment of pH 5.5, SC, aza nucleoside prodrugs ProD 1- 
ProD 3 may have a better bioavailability than their parent active drugs due to improved 
absorption. In addition, those prodrugs may be used in different dosage forms because of 
their potential solubility in organic and aqueous media due to the ability of the anilinium 
group to be converted to the corresponding aniline group in a physiological pH of 6.5. 
 
The selection of Kirby‘s enzyme model to be utilized as carriers to aza nucleosides is based 
on the fact that those carriers undergo proton transfer reaction to yield an aldehyde, an 
alcohol and a hydroxy amine. The rate-limiting step in these processes is a proton transfer 
from the anilinium group into the neighboring ether oxygen. Furthermore, the proton transfer 
rate is strongly dependent on the strength of the hydrogen bonding in the reactions transition 
states. Therefore, the reaction rate is greatly affected by the structural features of Kirby‘s 
enzyme model system as evident from the different experimental rate values determined for 
the different processes.
[144]
  
 
Karaman‘s DFT calculation results for intramolecular proton transfer reactions in Kirby‘s 
enzyme models revealed that the reaction rate is quite responsive to geometric disposition. 
For example, based on the calculated log EM, the cleavage process for prodrug ProD 1 was 
predicted to be about 10
10
 times faster than for prodrug ProD 2 and about 10
4
 times faster 
than prodrug ProD 3:rateProD1> rateProD3> rate ProD2. Hence, the rate by which the prodrug 
releases the aza nucleoside can be determined according to the structural features of the linker 
(Kirby‘s enzyme model). The three designed prodrugs were synthesized and characterized 
and in-vitro and in-vivo studies on their bioavailability are underway.
[144]
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Figure 11: Intramolecular cleavage of aza-nucleoside prodrugs ProD 1-ProD 3 to their 
corresponding parent active drugs. 
 
SUMMARY AND CONCLUSIONS 
There are two major prodrug design approaches: the first is the targeted drug design approach 
by which prodrugs can be designed to target specific enzymes or carriers by considering 
enzyme-substrate specificity or carrier-substrate specificity in order to overcome various 
undesirable drug properties. This type of "targeted-prodrug" design requires considerable 
knowledge of particular enzymes or carriers, including their molecular and functional 
characteristics.  
 
This approach has been accelerated after encouraging results emerged from several studies on 
targeted prodrugs that demonstrated better efficiency and safety profiles. 
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Active targeting of cancer cells can be achieved by targeting transporters present at these 
cells or by using chimeric/humanized mAbs. While passive targeting can be achieved by 
taking advantage of the EPR effect which is characteristic for tumor cells. Some conditions 
associated with tumors such as hypoxia and low pH are also considered as good methods for 
targeting. For prostate cancer specific linkers that can be cleaved by the highly expressed 
PSA were linked to a number of tested prodrugs. For targeting liver cancer HepDirect 
prodrugs and carbamate prodrugs were made, tested and are in use. In colon targeting all the 
developed prodrugs contain a labile bond that can be cleaved by the enzymes secreted by the 
colonic microflora, such as azo bond containing prodrugs or they are linked to specific 
conjugates that can be degraded only in the colon. 
 
Redox chemical delivery systems that contain pyridine have shown a good efficacy for CNS 
targeting. 
 
In targeting HIV, researchers have developed prodrugs to target macrophages by linking 
them to moieties that make the prodrug-conjugate capable of being internalized by receptor 
mediated endocytosis.  
 
Antibody directed enzyme prodrug therapy (ADEPT) is relatively new method for cancer 
treatment. It is a two-step approach where an antibody-drug activating enzyme conjugate 
(AEC) is given first to be targeted and localized into the tumor and accumulates 
predominantly at the tumor cells that have the wanted tumor associated antigen. In the second 
step a nontoxic prodrug is injected systemically to be converted to its corresponding active 
form with high tumor concentration by the localized enzyme. This method has advantages 
over the older cancer therapy and is considered as a promising approach in the area of cancer 
treatment. 
 
Alternative approaches designed to overcome the limitations of ADEPT are gene-directed 
enzyme prodrug therapy (GDEPT) and virus-directed enzyme prodrug therapy (VDEPT). In 
these approaches, genes encoding prodrug-activating enzymes are targeted to tumor cells 
followed by prodrug administration. In GDEPT, nonviral vectors that contain gene-delivery 
agents, such as peptides, cationic lipids or naked DNA, are used for gene targeting. In 
VDEPT, gene targeting is achieved using viral vectors, with retroviruses and adenoviruses 
being the most commonly used viruses. For both GDEPT and VDEPT, the vector has to be 
taken up by the target cells, and the enzyme must be stably expressed in tumor cells. This 
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process is called transduction.  GDEPT and VDEPT effectiveness has been limited to date by 
insufficient transduction of tumor cells in vivo.  
 
The second approach is the chemical design approach in which the drug is linked to inactive 
organic moiety which upon exposure to physiological environment releases the parent drug 
and a non-toxic linker which should be eliminated without affecting the clinical profile. 
 
Unraveling the mechanisms of a number of enzyme models has allowed for the design of 
efficient chemical devices having the potential to be utilized as prodrug linkers that can be 
covalently attached to commonly used drugs which can chemically, and not enzymatically, be 
converted to release the active drugs in a programmable manner. For instance, exploring the 
mechanism for Kirby‘s acetals has led to the design and synthesis of novel prodrugs of aza-
nucleosides for the treatment for myelodysplastic syndromes. In this example, the prodrug 
moiety was linked to the hydroxyl group of the active drug such that the drug-linker moiety 
(prodrug) has the potential to interconvert when exposed into physiological environments 
such as stomach, intestine, and/or blood circulation, with rates that are solely dependent on 
the structural features of the pharmacologically inactive promoiety (Kirby‘s enzyme model). 
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